高级检索
    冯海琼, 汪蓉, 赵顺春, 罗秀珍. 不同剂量瑞舒伐他汀对冠状动脉粥样硬化斑块及血管内皮细胞功能的影响[J]. 蚌埠医科大学学报, 2022, 47(3): 349-352. DOI: 10.13898/j.cnki.issn.1000-2200.2022.03.019
    引用本文: 冯海琼, 汪蓉, 赵顺春, 罗秀珍. 不同剂量瑞舒伐他汀对冠状动脉粥样硬化斑块及血管内皮细胞功能的影响[J]. 蚌埠医科大学学报, 2022, 47(3): 349-352. DOI: 10.13898/j.cnki.issn.1000-2200.2022.03.019
    shu
    FENG Hai-qiong, WANG Rong, ZHAO Shun-chun, LUO Xiu-zhen. Study on the effects of different doses of rosuvastatin on coronary atherosclerotic plaques and vascular endothelial cell function[J]. Journal of Bengbu Medical University, 2022, 47(3): 349-352. DOI: 10.13898/j.cnki.issn.1000-2200.2022.03.019
    Citation: FENG Hai-qiong, WANG Rong, ZHAO Shun-chun, LUO Xiu-zhen. Study on the effects of different doses of rosuvastatin on coronary atherosclerotic plaques and vascular endothelial cell function[J]. Journal of Bengbu Medical University, 2022, 47(3): 349-352. DOI: 10.13898/j.cnki.issn.1000-2200.2022.03.019
    shu

    不同剂量瑞舒伐他汀对冠状动脉粥样硬化斑块及血管内皮细胞功能的影响

    Study on the effects of different doses of rosuvastatin on coronary atherosclerotic plaques and vascular endothelial cell function

      摘要
    • 摘要:
      目的探讨不同剂量瑞舒伐他汀对冠状动脉粥样硬化斑块及血管内皮细胞功能的作用。
      方法选取冠状动脉粥样硬化病人86例，随机分为观察组和对照组，各43例。对照组采用小剂量瑞舒伐他汀(10 mg)治疗；观察组采用大剂量瑞舒伐他汀(20 mg)治疗，持续治疗3个月。比较2组病人血管体积、管腔体积、斑块体积及肱动脉血流介导的舒张功能(flow-mediated vasodilation, FMD)、硝酸甘油介导的舒张功能(nitroglycerine-mediated vasodilation, NMD)、一氧化氮(nitric oxide, NO)，记录不良反应发生情况。
      结果2组病人治疗前血管体积、管腔体积和斑块体积差异均无统计学意义(P > 0.05)；治疗后，观察组血管体积、管腔体积及斑块体积均较治疗前减小(P < 0.05)，且均小于对照组(P < 0.05~P < 0.01)。2组病人治疗前FMD、NMD和NO差异均无统计学意义(P > 0.05)；治疗后，2组病人FMD、NMD和NO均较治疗前升高，且观察组FMD、NMD和NO均明显高于对照组(P < 0.01)。2组病人治疗期间均未出现急性心血管事件，观察组不良反应发生率为9.30%(4/43)，与对照组的6.98%(3/43)差异无统计学意义(P > 0.05)。
      结论与10 mg瑞舒伐他汀相比，20 mg瑞舒伐他汀对冠状动脉粥样硬化斑块有助于改善硬化斑块和血管内皮细胞功能，且病人可以耐受，安全性较高。

       

      Abstract:
      ObjectiveTo investigate the effects of different doses of rosuvastatin on coronary atherosclerotic plaques and vascular endothelial cell function.
      MethodsEighty-six coronary atherosclerotic patients were randomly divided into the observation group and control gorup(43 cases in each gorup). The control group was treated with 10 mg of rosuvastatin, and the observation group was treated with 20 mg of rosuvastatin for 3 months. The volume of blood vessels, volume of lumen, volume of plaque, flow-mediated vasodilation(FMD), nitroglycerin-mediated vasodilation(NMD) and nitric oxide(NO) were compared between two groups, and the adverse reactions in two groups were also recorded.
      ResultsThere was no statistical significance in the vascular volume, lumen volume and plaque volume between two groups before treatment(P > 0.05). After treatment, the vascular volume, lumen volume and plaque volume in two groups decreased compared with those before treatment(P < 0.05), and which in observation group were less than those in control group(P < 0.05 to P < 0.01). There was no statistical significance in the FMD, NMD and NO between two groups before treatment(P > 0.05). After treatment, the FMD, NMD and NO in two groups increased compared with before treatment, and the FMD, NMD and NO in observation group were significantly higher than those in control group(P < 0.01). No acute cardiovascular events occurred in two groups during treatment. The incidence rate of adverse reactions in observation group and control group were 9.30%(4/43) and 6.98%(3/43), respectively, and the difference of which between two groups was not statistical significance(P > 0.05).
      ConclusionsCompared with 10 mg rosuvastatin, the 20 mg of rosuvastatin in the treatment of coronary atherosclerotic plaque can improve the plaque and vascular endothelial cell function, with good toleracnce and safety.

       

      • HTML全文
      • 参考文献(20)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回